Hi, I am Marmee Regine, your host in Pandemic Podcast Coronavirus. Today we will listen to an Ivermectin prophylactic study from India that Dr. John Campbell will discuss. Last March, I also published here on my podcast a special episode with Dr. Pierre Kory testified that Ivermectin is effectively a "miracle drug" against COVID-19 and informs all to prescribe Ivermectin for COVID-19. In the study that Dr. Campbell discusses the prophylactic role of oral Ivermectin. I believed in the expert opinion of Dr. Campbell, for he has a million subscribers in his channel. Let me read to all of you the background of this study online.515,687 views May 6, 2021, Dr. John Campbell 1.02M subscribers Ivermectin in India, Prophylactic role of Ivermectin in SARS-CoV-2 infection among healthcare workers https://www.aiims.edu/en.html https://assets.researchsquare.com/fil... https://www.researchsquare.com/articl... Background -Healthcare workers (HCWs) are vulnerable to getting infected with sars-CoV-2. Preventing HCWs from getting infected is a priority to maintain healthcare services. The therapeutic and preventive role of ivermectin in COVID-19 is being investigated. Based on promising results of in vitro studies of oral ivermectin, this study looks at the prophylactic role of oral ivermectin. 
Methods - The prospective cohort study was conducted at AIIMS Bhubaneswar. Two-doses of oral ivermectin, 300 μg/kg at a gap of 72 hours. Primary outcome, COVID-19 infection in the month following of 3892 employees, 3532 (90.8%) participated in the study Ivermectin uptake n = 2, 384 (67.5%) ; Non uptake, n = 1147 (32.5%). 
Results - Development of symptomatic infection 331 participants, developed symptoms 131 in takers 200 from non-takers Ivermectin takers, 6% Non-takers, 15% Testing positive, 201 Ivermectin takers, 2% Non-takers, 11.7%. Implications for transmission HCWs who had taken two-doses (Single dose did not reach significance) significantly lower risk of contracting COVID-19 disease during the following month was 0.18. Adjusted Relative Risk 0.17. 1.8% reported adverse events, mild and self-limiting. 
Conclusion and relevance - Two doses of oral ivermectin (300 μg/kg given 72 hours apart) as chemoprophylaxis among HCWs reduce the risk of COVID-19 infection by 83% in the following month. Safe, effective, and low-cost chemoprophylaxis has relevance in the containment of pandemics alongside vaccines.

Support the show (https://www.patreon.com/pandemicpodcastcoronavirus)